Company profile for Macomics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Macomics has a portfolio of antibody programs progressing towards the clinic. Our portfolio is diversified by the mechanism of action and is focussed on multi-hit biological hypothesis, modulating both TAM biology directly and the activity of the broader immune system, to re-invigorate immune responses against cancer cells.A key challenge in the field has been the translation of large Omic datasets into validated drug targets,...
Macomics has a portfolio of antibody programs progressing towards the clinic. Our portfolio is diversified by the mechanism of action and is focussed on multi-hit biological hypothesis, modulating both TAM biology directly and the activity of the broader immune system, to re-invigorate immune responses against cancer cells.A key challenge in the field has been the translation of large Omic datasets into validated drug targets, due to the lack of representative cell models. This requires the use of low throughput human monocyte-derived macrophage assays, which are unsuitable for target validation or drug testing at scale

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
United Kingdom
Address
Address
137a George Street, Edinburgh, Scotland EH2 4JY, GB
Telephone
Telephone
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.pharmiweb.com/press-release/2025-11-25/macomics-announces-updated-data-of-the-enigmac-drug-discovery-platform-and-the-role-of-macrophages-in-fibrotic-disease

PHARMIWEB
25 Nov 2025

https://www.globenewswire.com/news-release/2025/10/08/3163098/0/en/Macomics-Announces-Neurodegeneration-and-Neuroinflammation-Applications-of-ENIGMAC-Drug-Discovery-Platform.html

GLOBENEWSWIRE
08 Oct 2025

https://www.globenewswire.com/news-release/2024/06/19/2900940/0/en/Macomics-and-the-Institute-of-Oncology-Research-IOR-Switzerland-Announce-Macrophage-Scientific-Collaboration-in-Prostate-Cancer-Drug-Development.html

GLOBENEWSWIRE
19 Jun 2024

https://www.globenewswire.com/news-release/2024/06/10/2895766/0/en/Macomics-Announces-Appointment-of-Simon-Dew-as-New-Chief-Business-Officer.html

GLOBENEWSWIRE
10 Jun 2024

https://www.globenewswire.com/news-release/2024/05/13/2880136/0/en/Macomics-and-IFOM-the-AIRC-Institute-of-Molecular-Oncology-Announce-Macrophage-Scientific-Collaboration.html

GLOBENEWSWIRE
13 May 2024

https://www.globenewswire.com/news-release/2024/04/11/2861274/0/en/Macomics-Unveils-its-Lead-First-in-Class-Anti-Pan-LILRB-Monoclonal-Antibody-Programme-with-Positive-Pre-clinical-Data-Presented-at-AACR-2024.html

GLOBENEWSWIRE
11 Apr 2024

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty